PCM
TVTX icon

Prelude Capital Management’s Travere Therapeutics TVTX Stock Holding History

Prelude Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,000
Closed -$27K – 2043
2018
Q2 		$27K Buy
+1,000
New +$26.6K ﹤0.01% 1285
2016
Q4 		– Sell
-12,600
Closed -$282K – 1785
2016
Q3 		$282K Buy
+12,600
New +$240K 0.03% 453

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prelude Capital Management's TVTX Position: Q1 2026 in Review

Prelude Capital Management sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 20,599 shares — an estimated $787K sold.

Prelude Capital Management first reported a position in TVTX in Q2 2015 and held it in 19 quarters. The position peaked at $2.49M in Q3 2020. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Prelude Capital Management reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 20,599 Travere Therapeutics shares in Q1 2026, an estimated $787K.
  • Prelude Capital Management first reported a position in Travere Therapeutics in Q2 2015 and held it in 19 quarters.
  • Prelude Capital Management's Travere Therapeutics position peaked at $2.49M in Q3 2020.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.